Thursday, September 18, 2025
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects
CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene editing space thanks to its pipeline potential.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.